Lymphomas: Our Clinical Trials

In addition to providing excellent care, Memorial Sloan Kettering Cancer Center is constantly working to develop new and improved treatments for people with lymphoma who are not helped by standard treatments. This research is conducted through our clinical trials program.

Our physicians lead a large number of clinical trials that test new drugs and drug combinations, look for genetic factors that are linked to lymphoma, and explore other strategies for improving treatment for both Hodgkin and non-Hodgkin lymphoma. Our clinical trials are based on our growing understanding of how lymphoma is distinctive from other cancers. This research is increasingly “translational,” bringing discoveries made in the research lab directly to the patient.

This activity means that choosing Memorial Sloan Kettering for your care may give you access to new treatment options before they are widely available elsewhere. Our clinical research team is highly experienced in selecting patients who are mostly likely to benefit from a particular investigational therapy and can guide you through the process of selecting the most appropriate clinical trial.

Our research efforts fall into the following general categories:

New chemotherapy approaches

Our physicians are investigating the effectiveness of various combinations of chemotherapeutic agents and other drugs for non-Hodgkin lymphoma.

Pathway-directed (biologic) therapies

Our investigators are testing drugs designed to interrupt or inhibit the molecular processes tumor cells require to grow and spread.

Immune strategies

Memorial Sloan Kettering has an active immunotherapy program testing investigational drugs that encourage the body's immune system to identify and react against cancer cells.

Tumor-directed therapies (radiolabeled antibodies)

Memorial Sloan Kettering researchers are investigating the effectiveness of antibodies — proteins that specifically target cancer cells and carry radioactive molecules. These drugs can potentially kill cancer cells with radiation while minimizing exposure to the rest of the body.

Here you can find a continually updated listing of Memorial Sloan Kettering's current clinical trials for patients with lymphomas. To learn more about a study, choose from the list below.

Marginal Zone Lymphoma

Follicular Lymphoma

Untreated (Newly Diagnosed)

A Phase III Study of Rituximab/Lenalidomide or Rituximab/Chemotherapy Followed by Rituximab Maintenance Therapy in Patients with Previously Untreated Follicular Lymphoma
Palomba, M. Lia, MD
[Protocol 12-081]

A Phase II Study of Ibrutinib plus Rituximab in Patients with Previously Untreated Follicular Lymphoma
Palomba, M. Lia, MD
[Protocol 14-018]

Prior Treatment (Relapsed/Refractory)

A Phase I Study of PRT062070 in Patients with Persistent or Recurrent Chronic Lymphocytic Leukemia, Small Cell Lymphocytic Leukemia, or B-Cell Non-Hodgkin Lymphoma
Hamlin, Paul, MD
[Protocol 14-023]

A Phase I Study of CB-839 in Patients with Advanced or Persistent Hematologic Cancers
Younes, Anas, MD
[Protocol 14-053]

A Phase I Study of CPI-0610 in Patients with Progressive Lymphoma
Younes, Anas, MD
[Protocol 13-259]

A Phase IB Study of MK-3475 in Patients with Myelodysplastic Syndromes and Lymphoma
Moskowitz, Craig, MD
[Protocol 13-220]

A Phase Ib Study of Urelumab Given with Rituximab in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Zelenetz, Andrew, MD, PhD
[Protocol 13-252]

A Phase I Study of ABT-199 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma
Gerecitano, John, MD, PhD
[Protocol 11-152]

A Phase IB/IIA Study of Romidepsin plus Lenalidomide in Adults with Relapsed or Refractory Lymphoma and Myeloma
Horwitz, Steven, MD
[Protocol 12-170]

A Phase I Study of CUDC-907 in Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
Younes, Anas, MD
[Protocol 13-045]

A Phase I Study of IMGN529 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Palomba, M. Lia, MD
[Protocol 13-073]

Small Lymphocytic Lymphoma (SLL)

Diffuse Large B-Cell Lymphoma

Untreated (Newly Diagnosed)

A Phase III Study of Ibrutinib (PCI-32765) plus R-CHOP Chemotherapy in Patients Newly Diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL)
Younes, Anas, MD
[Protocol 13-146]

A Phase III Study of Ibritumomab Tiuxetan versus Observation in Older Patients with Diffuse Large B-Cell Lymphoma in Remission following R-CHOP
Hamlin, Paul, MD
[Protocol 12-061]

A Phase II Study of Dose-Adjusted EPOCH Chemotherapy with or without Rituximab in Patients with Untreated Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, or Plasmablastic Lymphoma
Noy, Ariela, MD
[Protocol 13-022]

Prior Treatment (Relapsed/Refractory)

A Phase I Study of PRT062070 in Patients with Persistent or Recurrent Chronic Lymphocytic Leukemia, Small Cell Lymphocytic Leukemia, or B-Cell Non-Hodgkin Lymphoma
Hamlin, Paul, MD
[Protocol 14-023]

A Phase I Study of CB-839 in Patients with Advanced or Persistent Hematologic Cancers
Younes, Anas, MD
[Protocol 14-053]

A Phase I Study of CPI-0610 in Patients with Progressive Lymphoma
Younes, Anas, MD
[Protocol 13-259]

A Phase IB Study of MK-3475 in Patients with Myelodysplastic Syndromes and Lymphoma
Moskowitz, Craig, MD
[Protocol 13-220]

A Phase Ib Study of Urelumab Given with Rituximab in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Zelenetz, Andrew, MD, PhD
[Protocol 13-252]

A Phase I Study of ABT-199 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma
Gerecitano, John, MD, PhD
[Protocol 11-152]

A Phase IB/IIA Study of Romidepsin plus Lenalidomide in Adults with Relapsed or Refractory Lymphoma and Myeloma
Horwitz, Steven, MD
[Protocol 12-170]

A Phase I Study of CUDC-907 in Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
Younes, Anas, MD
[Protocol 13-045]

A Phase I Study of High-Dose Therapy and Autologous Stem Cell Transplantation Followed by Modified T Cells for Aggressive B-Cell Non-Hodgkin Lymphoma
Sauter, Craig, MD
[Protocol 12-117]

A Phase I Study of IMGN529 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Palomba, M. Lia, MD
[Protocol 13-073]

Hodgkin Lymphoma

Untreated (Newly Diagnosed)

A Phase II Study of Brentuximab (SGN-35) Given Before and After Adriamycin, Vinblastine, and Dacarbazine Therapy in Older Adults with Untreated Hodgkin Lymphoma
Hamlin, Paul, MD
[Protocol 11-201]

A Pilot Study of Brentuximab Vedotin with Chemotherapy and Radiation Therapy in Early-Stage Poor-Risk Newly Diagnosed Hodgkin Lymphoma
Moskowitz, Craig, MD
[Protocol 13-034]

A Randomized Phase III Study of Standard Chemotherapy with and without Brentuximab in Patients Newly Diagnosed with Advanced Hodgkin Lymphoma
Straus, David, MD
[Protocol 13-056]

Prior Treatment (Relapsed/Refractory)

Non-Comparative, Two-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Classical Hodgkin Lymphoma (cHL) Subjects After Failure of Autologous Stem Cell Transplant (ASCT)

A Phase I Study of CPI-0610 in Patients with Progressive Lymphoma
Younes, Anas, MD
[Protocol 13-259]

A Phase IB Study of MK-3475 in Patients with Myelodysplastic Syndromes and Lymphoma
Moskowitz, Craig, MD
[Protocol 13-220]

A Phase IB/IIA Study of Romidepsin plus Lenalidomide in Adults with Relapsed or Refractory Lymphoma and Myeloma
Horwitz, Steven, MD
[Protocol 12-170]

A Phase I Study of CUDC-907 in Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
Younes, Anas, MD
[Protocol 13-045]

A Phase I Study of Brentuximab Vedotin plus Temsirolimus in Relapsed and Refractory Hodgkin Lymphoma
Moskowitz, Alison, MD
[Protocol 13-044]

Brentuximab (SGN-35) in Transplant-Eligible Patients with Relapsed or Refractory Hodgkin Lymphoma
Moskowitz, Alison, MD
[Protocol 11-142]

Mantle Cell Lymphoma

Untreated (Newly Diagnosed)

A Phase III Study of Bendamustine and Rituximab with or without Ibrutinib in Older Patients with Newly Diagnosed Mantle Cell Lymphoma
Hamlin, Paul, MD
[Protocol 13-196]

Ofatumumab with or without Bendamustine for Patients with Mantle Cell Lymphoma Who Cannot Have an Autologous Stem Cell Transplant
Hamlin, Paul, MD
[Protocol 11-050]

Prior Treatment (Relapsed/Refractory)

A Phase I Study of PRT062070 in Patients with Persistent or Recurrent Chronic Lymphocytic Leukemia, Small Cell Lymphocytic Leukemia, or B-Cell Non-Hodgkin Lymphoma
Hamlin, Paul, MD
[Protocol 14-023]

A Phase I Study of CB-839 in Patients with Advanced or Persistent Hematologic Cancers
Younes, Anas, MD
[Protocol 14-053]

A Phase I Study of CPI-0610 in Patients with Progressive Lymphoma
Younes, Anas, MD
[Protocol 13-259]

A Phase Ib Study of Urelumab Given with Rituximab in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Zelenetz, Andrew, MD, PhD
[Protocol 13-252]

A Phase IB Study of MK-3475 in Patients with Myelodysplastic Syndromes and Lymphoma
Moskowitz, Craig, MD
[Protocol 13-220]

A Phase I Study of CUDC-907 in Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
Younes, Anas, MD
[Protocol 13-045]

A Phase I Study of High-Dose Therapy and Autologous Stem Cell Transplantation Followed by Modified T Cells for Aggressive B-Cell Non-Hodgkin Lymphoma
Sauter, Craig, MD
[Protocol 12-117]

A Phase IB/IIA Study of ABT-888 in Combination with Bendamustine with or without Rituximab in Patients with Lymphoma, Multiple Myeloma, and Solid Tumors
Gerecitano, John, MD, PhD
[Protocol 10-174]

A Phase I Study of IMGN529 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Palomba, M. Lia, MD
[Protocol 13-073]

Burkitt's Lymphoma

T Cell Lymphoma

HIV+ Lymphoma

Waldenstrom's Macroglobulinemia

Adult T Cell Leukemia Lymphoma

Phase I Trials

Phase 1/2 Open-Label, Multiple-dose, Dose-escalation Study to Evaluate the Safety and Tolerability of IMO-8400 in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

A Phase I Study of PRT062070 in Patients with Persistent or Recurrent Chronic Lymphocytic Leukemia, Small Cell Lymphocytic Leukemia, or B-Cell Non-Hodgkin Lymphoma
Hamlin, Paul, MD
[Protocol 14-023]

A Phase I Study of CB-839 in Patients with Advanced or Persistent Hematologic Cancers
Younes, Anas, MD
[Protocol 14-053]

A Phase I Study of CPI-0610 in Patients with Progressive Lymphoma
Younes, Anas, MD
[Protocol 13-259]

A Phase Ib Study of Urelumab Given with Rituximab in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Zelenetz, Andrew, MD, PhD
[Protocol 13-252]

A Phase IB Study of MK-3475 in Patients with Myelodysplastic Syndromes and Lymphoma
Moskowitz, Craig, MD
[Protocol 13-220]

A Study of Bortezomib plus (R)ICE in Subjects with Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Noy, Ariela, MD
[Protocol 09-063]

A Phase I Study of ABT-199 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma
Gerecitano, John, MD, PhD
[Protocol 11-152]

A Phase I Study of High-Dose Therapy and Autologous Stem Cell Transplantation Followed by Modified T Cells for Aggressive B-Cell Non-Hodgkin Lymphoma
Sauter, Craig, MD
[Protocol 12-117]

A Phase I Study of Brentuximab Vedotin plus Temsirolimus in Relapsed and Refractory Hodgkin Lymphoma
Moskowitz, Alison, MD
[Protocol 13-044]

A Phase I Study of CUDC-907 in Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
Younes, Anas, MD
[Protocol 13-045]

A Phase I Study of IMGN529 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Palomba, M. Lia, MD
[Protocol 13-073]

A Phase IB/IIA Study of ABT-888 in Combination with Bendamustine with or without Rituximab in Patients with Lymphoma, Multiple Myeloma, and Solid Tumors
Gerecitano, John, MD, PhD
[Protocol 10-174]